Adjuvant system AS01: helping to overcome the challenges of modern vaccines

Introduction: Adjuvants are used to improve vaccine immunogenicity and efficacy by enhancing antigen presentation to antigen-specific immune cells with the aim to confer long-term protection against targeted pathogens. Adjuvants have been used in vaccines for more than 90 years. Combinations of immu...

Full description

Saved in:
Bibliographic Details
Main Authors: Arnaud M. Didierlaurent (Author), Béatrice Laupèze (Author), Alberta Di Pasquale (Author), Nadia Hergli (Author), Catherine Collignon (Author), Nathalie Garçon (Author)
Format: Book
Published: Taylor & Francis Group, 2017-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_e4e83bb0a82e4bf49eec7f45bd0bc81a
042 |a dc 
100 1 0 |a Arnaud M. Didierlaurent  |e author 
700 1 0 |a Béatrice Laupèze  |e author 
700 1 0 |a Alberta Di Pasquale  |e author 
700 1 0 |a Nadia Hergli  |e author 
700 1 0 |a Catherine Collignon  |e author 
700 1 0 |a Nathalie Garçon  |e author 
245 0 0 |a Adjuvant system AS01: helping to overcome the challenges of modern vaccines 
260 |b Taylor & Francis Group,   |c 2017-01-01T00:00:00Z. 
500 |a 1476-0584 
500 |a 1744-8395 
500 |a 10.1080/14760584.2016.1213632 
520 |a Introduction: Adjuvants are used to improve vaccine immunogenicity and efficacy by enhancing antigen presentation to antigen-specific immune cells with the aim to confer long-term protection against targeted pathogens. Adjuvants have been used in vaccines for more than 90 years. Combinations of immunostimulatory molecules, such as in the Adjuvant System AS01, have opened the way to the development of new or improved vaccines. Areas covered: AS01 is a liposome-based vaccine adjuvant system containing two immunostimulants: 3-O-desacyl-4ʹ-monophosphoryl lipid A (MPL) and the saponin QS-21. Here we describe studies investigating the mode of action of AS01, and consider the role of AS01 in enhancing specific immune responses to the antigen for selected candidate vaccines targeting malaria and herpes zoster. The effects of AS01 are rapid and transient, being localized to the injected muscle and draining lymph node. AS01 is efficient at promoting CD4+ T cell-mediated immune responses and is an appropriate candidate adjuvant for inclusion in vaccines targeting viruses or intracellular pathogens. Expert commentary: AS01 activity to enhance adaptive responses depends on synergistic activities of QS-21 and MPL. AS01 adjuvantation shows good prospects for use in new vaccines targeted to populations with challenging immune statuses and against diseases caused by complex pathogens. 
546 |a EN 
690 |a vaccine 
690 |a adjuvant 
690 |a as01 
690 |a safety 
690 |a immunogenicity 
690 |a immune response 
690 |a innate immune response 
690 |a adaptive immune response 
690 |a Internal medicine 
690 |a RC31-1245 
655 7 |a article  |2 local 
786 0 |n Expert Review of Vaccines, Vol 16, Iss 1, Pp 55-63 (2017) 
787 0 |n http://dx.doi.org/10.1080/14760584.2016.1213632 
787 0 |n https://doaj.org/toc/1476-0584 
787 0 |n https://doaj.org/toc/1744-8395 
856 4 1 |u https://doaj.org/article/e4e83bb0a82e4bf49eec7f45bd0bc81a  |z Connect to this object online.